New therapies and vaccines for bacterial meningitis

Bibliography

• KAPLAN SL: Clinical presentations, diagnosis and prognostic factors of bacterial meningitis. Infect. Dis. Clin. North Am. (1999) 13:579–594.
   PubMed Web of Science ®Google Scholar
• ••Excellent review.
   Google Scholar
• SEGRETTIJ, HARRIS AA: Acute bacterial meningitis. Infect. Dis. Clin. North Am. (1996) 10:707–809.
   Google Scholar
• WENGER JD, HIGHTOWER AW, FACKLAM RR et al.: Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. The Bacterial Meningitis Study Group. I Infect. Dis. (1990) 162:1316–1323.
   PubMed Web of Science ®Google Scholar
• SCHUCHAT A, ROBINSON K, WENGWER JD et al: Bacterial Meningitis in the United States in 1995: N Engl. J. Med. (1997) 337:970–976.
   Google Scholar
• TIKHOMIROV E, SANTAMARIA M, ESTEVES K: Meningococcal disease: public health burden and control. World Health Stat. Q. (1997) 50:170–177.
   PubMedGoogle Scholar
• PONG A, BRADLEY JS: Bacterial meningitis and the newborn infant. Infect. Dis. Clin. North Am. (1999) 13:711–733.
   Google Scholar
• ••Excellent review of neonatal meningitis.
   Google Scholar
• GOLD R: Epidemiology of bacterial meningitis. Infect. Dis. Clin. North Am. (1999) 13:515–525.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of epidemiologythroughout the world.
   Google Scholar
• BEDFORD H, DE LOU VOIS J, HALKET S, PECKHAM C, HURLEY R, HARVEY D: Meningitis in infancy in England and Wales: follow-up at age 5 years. Br. Med. J. (2001) 323:533–536.
   PubMed Web of Science ®Google Scholar
• •Review of long term follow up of bacterial meningitis in infancy.
   Google Scholar
• LEIB SL, TAUBER MG: Pathogenesis of bacterial meningitis. Infect. Dis. Clin. North Am. (1999) 13:527–548.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of pathophysiology.
   Google Scholar
• WAAGE A, HALSTENSEN A, SHALABY S et al.: Local production of tumor necrosis factor alpha, interleukin 1 and interleukin 6 in meningococcal meningitis. I Exp. Med. (1989) 170:1859–1867.
   PubMed Web of Science ®Google Scholar
• TAUBER MG, MOSER B: Cytokines and chemokines in meningeal inflammation: biology and clinical implications. Clin. Infect. Dis. (1999) 28:1–12.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of cytokine biology.
   Google Scholar
• RAMILIO 0, SAEZ-LLORENS X, MERTOSOLA J et al:Tumor necrosis factor alpha/cachectin and interleukin 1 beta initiate meningeal inflammation. Exp. Med. (1990) 172:4367–4375.
   Google Scholar
• FASSENBENDER K, SCHMINKE HF, REIS S et al.: Endothelial-derived adhesion molecules in bacterial meningitis: association to cytokine release and intrathecal leukocyte recruitment. J. Neuroimmunol (1997) 74:130–134.
   PubMed Web of Science ®Google Scholar
• KIM KS, WASS CA, CROSS AS, OPAL SM: Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat. Lymphokine Cytokine Res. (1992) 11:293–298.
   PubMedGoogle Scholar
• SHARIEF MK, CIARDI M, THOMPSON EJ: Blood-brain barrier damage in patients with bacterial meningitis: association with tumor necrosis factor-a but not interleukin-1 B. Infect. Dis. (1992) 166:350–358.
   Google Scholar
• TAUBER MG: Brain oedema, intracranialpressure and cerebral blood flow in bacterial meningitis. Pediati: Infect. Dis. 1 (1989) 8:915-917.
   Google Scholar
• FELDMAN WE: Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis. J. Pediatr. (1976) 88:549–552.
   PubMed Web of Science ®Google Scholar
• PELTOLA H, ANTTILA M, RENKONEN OV: Randomised comparison of chloramphenicol, ampicillin, cefotaxime and ceftriaxone for childhood bacterial meningitis. Finnish Study Group. Lancet (1989) I(8650):1281–1287.
   Google Scholar
• ••Original study of antimicrobialpenetration.
   Google Scholar
• QUARLIARELLO VJ, SCHELD WM: Treatment of bacterial meningitis. N Engl. Med. (1997) 336:708–716.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of treatment.
   Google Scholar
• HANSMAN D, BULLEN MM: A resistantpneumococcus. Lancet (1967) 11:264–265.
   Google Scholar
• NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS: Performance standards for antimicrobial testing. Fifth International Supplement M10-55. Villanova (PA): National Committee for Clinical Laboratory Standards, 1994.
   Google Scholar
• MARTON A, GULYAS M, MUNOZ R et al.: Extremely high incidence of antibiotic resistance of Streptococcus pneumoniae in Hungary.' Infect. Dis. (1991) 163:524–548.
   Google Scholar
• FENOLL Al, JADO D, VICIOSO A etal.: Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990–1996). J. Gin. Microbial. (1998) 36:3447–3454.
   Google Scholar
• HOFFMAN J, CETRON MS, FARLEY MM et al.: The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl. J. Med. (1995) 333:481–486.
   PubMed Web of Science ®Google Scholar
• REACHER MH, SHAH A, LIVERMORE DM et al.: Bacteraemia and antibiotic resistance of pathogens reported in England and Wales between 1990 and 1998: trend analysis. Br. Med. J. (2000) 320:213–216.
   PubMed Web of Science ®Google Scholar
• ENRIGHT MC, FENOLL A, GRIFFITHS D et al.: The three major Spanish clones of penicillin-resistant Streptococcus pneumoniae are the most common clones recovered in recent cases of meningitis in Spain. I. Clin. Microbial. (1999) 37:3210–3216.
   PubMed Web of Science ®Google Scholar
• JOHN CC: Treatment failure with the use of third generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review. Clin. Infect. Dis. (1994) 18:188–193.
   PubMed Web of Science ®Google Scholar
• PALLARES R, LINARES J, VADILLO M et al.: Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl. J. Med. (1995) 333:474–480.
   PubMed Web of Science ®Google Scholar
• TAN TQ, MASON EO, BARSON WJ et al.: Clinical characteristics and outcome in children with pneumonia attributable to penicillin-susceptible and penicillin-nonsusceptible Streptococcus pneumoniae. Pediatrics (1998) 102:1369–1375.
   PubMed Web of Science ®Google Scholar
• TAN TQ, SCHUTZE GE, MASON OE et al.: Antibiotic therapy and acute outcome in meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins. Antimicrob. Agents Chemother. (1994) 38:918–923.
   PubMed Web of Science ®Google Scholar
• AMERICAN ACADEMY OF PAEDIATRICS. COMMITTEE ON INFECTIOUS DISEASES: Therapy for children with invasive pneumococcal infection. Pediatrics (1997) 99:289–299.
   PubMedGoogle Scholar
• VILADRICH PF, GUIDOL F, LINARES J et al.: Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob. Agents Chemother. (1991) 35:2467–2472.
   PubMed Web of Science ®Google Scholar
• PARIS MM, HICKEY SM, USCHER MI etal.: Effect of dexamethasone on therapy of experimental penicillin-resistant and cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. (1994) 38:1320–1324.
   Google Scholar
• KLUGMAN KP, FRIEDLAND IR, BRADLEY JS et al.: Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob. Agents Chemother. (1995) 39:1988–1992.
   PubMed Web of Science ®Google Scholar
• SAEZ-NIETO JA, LUJAN R, BERRON Set al.: Epidemiology and molecular basis of penicillin-resistant Neisseria meningitidisin Spain: a 5 year history (1985–1990). Clin. Infect. Dis. (1992) 14:394–402.
   Google Scholar
• KLUGMAN KP, MADHI SA: Emergence of drug resistance: impact on bacterial meningitis. Infect. Dis. Clin. North Am. (1999) 13:637–646.
   PubMed Web of Science ®Google Scholar
• •Good overview.
   Google Scholar
• MANDELMAN PM, CAUGENT DA, KALTZOGLOU G et al.: Genetic diversity of penicillin G resistant Neisseria meningitidis from Spain. Infect. Immun. (1989) 57:1025–1029.
   PubMed Web of Science ®Google Scholar
• OPPENHEIMER BA: Antibiotic resistance in Neisseria meningitidis. Clin. Infect. Dis. (1997) 24\(Suppl. 1):598–S101.
   Google Scholar
• LUCAS CUBELLS C, GARCIA GARCIA JJ, ROCA MARTINEZ Jet al.: Clinical data in children with meningococcal meningitis in a Spanish hospital. Acta Paediatr. (1997) 86(1):26–29.
   Google Scholar
• ALMOG R, BLOCK C, GDALEVITCH M et al: First recorded outbreaks of meningococcal disease in the Israeli defence force: three clusters due to serogroup C and the emergence of resistance to rifampicin. Infection (1994) 22:67–71.
   Google Scholar
• GRUNEBERG RN, FLEMINGHAM D: Results of the Alexander Project: a continuing, multicenter study of antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. Diagn. Microbial. Infect. Dis. (1996) 25(0169–184.
   PubMed Web of Science ®Google Scholar
• JOHNSON AW, MOKUOLU OA, ONILE BA. Chloramphenicol resistant Haemophilus Influenzae meningitis in young urban Nigerian children. Acta Paediam (1992) 81(11):941–943.
   Google Scholar
• ODIO CM, PUIG JR, FERIS JM et al.: Prospective randomized, investigator-blinded study of the efficacy and safety of meropenem versus cefotaxime in bacterial meningitis in children. Meropenem Meningitis Study Group. Pediam Infect. Dis. J. (1999) 18(7):581–590.
   PubMed Web of Science ®Google Scholar
• KIM B-N, WOO J-H, KIM Y-S et al.: Time-kill studies of antimicrobial combinations including cefotaxime, ceftriaxone, vancomycin and meropenem against cephalosporin-resistant Streptococcus pneumoniae. Chemotherapy (2000) 46(5):303–308.
   PubMed Web of Science ®Google Scholar
• NORRBY SR: Carbapenems in serious infections. A risk-benefit assessment. Drug Sal (2000) 22(3):191–194.
   Google Scholar
• NAU R, SCHMIDT T, KAYE K FROULA JL, TAUBER MG: Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits. Antimicrob. Agents Chemother. (1995) 39:583–597.
   Google Scholar
• OSTERGAARD C, SORENSON TK, KNUDSEN JD, FRIMODT-MOLLER N: Evaluation of mwdfloxacin, a new 8-methoxyquinolone, for the treatment of meningitis caused by a penicillin-reistant pneumococcus in rabbits. Antimicrob. Agents Chemother. (1998) 42:1706–1712.
   PubMed Web of Science ®Google Scholar
• COTTAGNOUD P, ACOSTA F, COTTAGNOUD M, NEFTEL K, TAUBER MG: Synergy between trovafloxacin and ceftriaxone against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro. Antimicrob. Agents Chemother. (2000) 44:2179–2181.
   PubMed Web of Science ®Google Scholar
• LIPSKY BA, BAKER CA: Fluroquinolone toxicity profiles: A review focusing on newer agents. Clin. Infect. Dis. (1999) 28:352–364.
   PubMed Web of Science ®Google Scholar
• STAHLMANN R, KUHNER S, SHAKIBIAEI M et al.: Chondrotoxicity of ciprofloxacin in immature beagle dogs: immunohistochemistry, electron microscopy and drug plasma concentrations. Arch. Toxicol (2000) 73:564–572.
   PubMed Web of Science ®Google Scholar
• BONFIGLIO G, FURNERI PM: Novel streptogramin antibiotics. Expert Opin. Investig. Drugs. (2001) 10:185–198.
   PubMed Web of Science ®Google Scholar
• •Good review of streptograrnins.
   Google Scholar
• LING TKW, FUNG KSC, CHENG AFB: In vitro activity and post-antibiotic effect of quinpristin/dalfopristin (Synercid). Chemotherapy (2001) 47:243–249.
   PubMed Web of Science ®Google Scholar
• GAREY KW, TESORO E, MUGGIA V, PASQUIER 0, ROD VOLD KA: Cerebrospinal fluid concerntrations of quinupristin-dalfopristin in a patient with vancomycin-resistant Enterococcus faecalis ventriculitis. Pharmacotherapy (2001) 21:748–750.
   PubMed Web of Science ®Google Scholar
• PERRY CM, JARVIS B: Linezolid: A review of its use in the management of serious Gram-positive infections. Drugs (2001) 61:525–551.
   PubMed Web of Science ®Google Scholar
• KAPLAN SL, PATTERSON L, EDWARDS KM et al.: Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Pediatr. Infect. Dis. (2001) 20:488–494.
   Google Scholar
• WILSON SE: Clinical trial results with linezolid, an oxazolidinone, in the treatment of surgical soft tissue and postoperative Gram-positive infections. Surg Infect. (2001) 2:25–35.
   PubMedGoogle Scholar
• ZEANA C, KUBIN KJ, DELLA-LATTA P, HAMMER SM: Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: Case report and review of the literature. Clin. Infect. Dis. (2001) 33:477–482.
   PubMed Web of Science ®Google Scholar
• COTTAGNOUD P, GERBER CM, ACOSTA F et al: Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model. Antimicrob. Agents Chemother. (2000) 46:981–985.
   Web of Science ®Google Scholar
• TAUBER MG, KHAYAM-BASHI H, SANDE MA: Effects of ampicillin and corticosteroids on brain water content, cerebrospinal fluid pressure and cerebrospinal fluid lactate levels in experimental pneumococcal meningitis. Infect. Dis. (1985) 151:528–534.
   Web of Science ®Google Scholar
• KADURUGAMUWA JL, HENGSTLER B, ZAK 0: Cerebrospinal fluid protein profile in experimental pneumococcal meningitis and its alteration by ampicillin and anti-inflammatory agents. I Infect. Dis. (1995) 159:26–34.
   Google Scholar
• ODIO CM, FAINGEZICHT I, PARIS M et al.: The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Eng. Med. (1991) 324:1525–1531.
   PubMed Web of Science ®Google Scholar
• ••First properly conducted study showingthe benefits of steroids.
   Google Scholar
• GIRGIS NI, FARID Z, MIKHAIL IA et al.: Dexamethasone treatment for bacterial meningitis in children and adults. Ped. Infect. Dis. J. (1989) 8:848–851.
   PubMed Web of Science ®Google Scholar
• KANRA GY, OZEN KD, SECMEER G et al.: Beneficial effects of dexamethasone in children with pneumococcal meningitis. Ped. Infect. Dis. J. (1995) 14:490–494.
   PubMed Web of Science ®Google Scholar
• ARDITI M, MASON EO Jr, BRADLEY JSet al: Three-year multicentre surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics (1998) 102:1087–1097.
   PubMed Web of Science ®Google Scholar
• MCINTYRE PB, BERKEY CS, KING SM et al.: Dexamethasone as adjunctive therapy in bacterial meningitis: a meta-analysis of randomized clinical trials since 1988. JAMA (1997) 278:925–931.
   PubMed Web of Science ®Google Scholar
• •Large meta-analysis of an unresolved issue.
   Google Scholar
• THOMAS R, LETULZO Y, BONGET C et al.: Trial of dexamethasone treatment for severe bacterial meningitis in adults. Adult Meningitis Steroid Group. Intensive Care Med. (1999) 25:475–480.
   PubMed Web of Science ®Google Scholar
• AHMAD A, JAFRI H, LUTSAR I et al.: Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antlinicrob. Agents Chemother. (1999) 43:876–881.
   PubMed Web of Science ®Google Scholar
• CARBELLOS C, MARTINEZ-LACASA J, TUBAU F et al: Evaluation of combined ceftriaxone and dexamethasone therapy in experimental cephalosporin-resistant pneumococcal meningitis. Antlinicrob. Agents Chemother. (2000) 45:315–320.
   Web of Science ®Google Scholar
• RAPPAPORT JM, BHATT SM, BURKARD RF et al.: Prevention of hearing loss in experimental pneumococcal meningitis by the administration of dexamethasone and ketolorac. J. Infect. Dis. (1999) 179:264–268.
   PubMed Web of Science ®Google Scholar
• CHEZ M, SILA CA, RANSOHOFF RM, LONGWORTH DL, WEIDA C: Ibuprofen-induced meningitis: detection of intrathecal IgG synthesis and immune complexes. Neurology (1990) 40:866–867.
   PubMedGoogle Scholar
• KORNELISSE RE HACK CE, SAVELKOUL HFJ et al.: Intrathecal production of interleukin-12 and gamma interferon in patients with bacterial meningitis. Infect. Inman. (1997) 65:877–881.
   Google Scholar
• OHGA S, AOKI T, OKADA K et al: Cerebrospinal fluid concentrations of interleukin-1 beta, tumor necrosis factor-alpha and interferon gamma in bacterial meningitis. Arch. Dis. Child. (1994) 70:123–125.
   PubMed Web of Science ®Google Scholar
• GLIMAKER M, OLCEN P, ANDERSSON B: Interferon gamma in cerebrospinal fluid from patients with viral and bacterial meningitis. Scand. J. Infect. Dis. (1994) 26:141–147.
   PubMed Web of Science ®Google Scholar
• COLE AM, GANZ T, LIESE AM et al: Cutting edge: IFN-inducible ELR-CXC chemokines display defensin-like antimicrobial activity.' Irronunol (2001) 167:623–627.
   PubMed Web of Science ®Google Scholar
• MACKENZIE CR, WILLBERG CB, DAUBENER W: Inhibition of group B streptococcal growth by IFNgamma-activated human glioblastoma cells.' Neuroinonunol (1998) 89:191–197.
   PubMed Web of Science ®Google Scholar
• VAN FURTH AM, SEIJMONSBERG EM, LANGERMANS JA et al.: High levels of interleukin-10 and tumor necrosis factor-alpha in cerebrospinal fluid during onset of bacterial meningitis. Cilia. Infect. Dis. (1995) 21:220–222.
   PubMed Web of Science ®Google Scholar
• PARK WS, CHANG YS, KO SY et al.: Efficacy of anti-tumor necrosis factor-alpha antibody as an adjunctive therapy in experimental Escherichia coli meningitis in the newborn piglet. Biol. Neonate (1999) 75:377–387.
   PubMedGoogle Scholar
• BOGDEN I, LEIB SL, BERGERON M, CHOW L, TAUBER MG: Tumor necrosis factor-alpha contributes to apoptosis in hippocampal neurons during experimental group B streptococcal meningitis. I Infect. Dis. (1997) 176:693–697.
   PubMed Web of Science ®Google Scholar
• ABRAHAM E, WUNDERINK R, SILVERMAN H et al.: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blinded, multicentre clinical trial. TNF-alpha Mab Sepsis Study Group. JAMA (1995) 273:934–941.
   Google Scholar
• COHEN J, CARLET J et at.: INTERSEPT:an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis. International Sepsis Trial Study Group. Crit. Care Med. (1996) 24:1413–1440.
   Google Scholar
• SAEZ-LLORENS X, RAMILO 0, MUSTAFA MM et al.: Pentoxifylline modulates meningeal inflammation in experimental bacterial meningitis. Antlinicrob. Agents Chen-wilier: (1990) 34:837–843.
   Google Scholar
• BURROUGHS M, TSENOVA-BERKOVA L, SOKOL K et al.: Effect of thalidomide on the inflammatory response in cerebrospinal fluid in experimental bacterial meningitis. Microb. Pathog. (1995) 19:245–255.
   PubMed Web of Science ®Google Scholar
• PARIS MM, HICKEY SM, TRUJILLO M et al.: The effect of interleukin-10 on meningeal inflammation in experimental bacterial meningitis. Infect. Dis. (1997) 176:1239–1246.
   Web of Science ®Google Scholar
• RAY G, ANEJA S, JAIN M, BATRA S: Evaluation of the free radical status in CSF in childhood meningitis. Annals Trop. Paed. (2000) 182:347–350.
   Google Scholar
• CHRISTEN S, SCHAPER M, LYKKESFELDT J: addaive stress in bacterial meningitis: Differential effects of [alpha]-phenyl-tert-butyl nitrone and N-acetylcysteine treatment. Free Radical Biol. Med. (2001) 31:754–762.
   PubMed Web of Science ®Google Scholar
• AUER M, PFISTER L-A, LEPPERT D, TAUBER MG, LEIB SL: Effects of clinically used antioxidants in experimental pneumococcal meningitis. J. Infect. Dis. (2000) 182:347–350.
   PubMed Web of Science ®Google Scholar
• KOEDEL U, PFISTER H-W: Protective effects of the antioxidant N-acetyl-L-cysteine in pneumococcal meningitis in rats. NeuroscL Lett. (1997) 225:33–36.
   PubMed Web of Science ®Google Scholar
• GARNET C, RAUD J, XIE X, LINDQUIST L, LINDBOM L: Inhibition of leukocyte rolling with polysaccharide fucoidin prevents pleocytosis in experimental meningitis in the rabbit. Clin. Invest. (1994) 93:929–936.
   Google Scholar
• GARNET C, RAUD J, LINDQUIST L: The polysaccharide fucoidin inhibits the antibiotic-induced inflammatory cascade in experimental pneumococcal meningitis. Clin. Diag. Lab. Innnunol (1998) 54:322–324.
   Google Scholar
• GARNET C, RAUD J, WAAGE A, LINDQUIST L: Effects of the polysaccharide fucoidin on cerebrospinal fluid interleukin-1 and tumor necrosis factor alpha in pneumococcal meningitis in the rabbit. Infect. Inonunol (1999) 67:2071–2074.
   PubMed Web of Science ®Google Scholar
• DEL MASCHIO A, DE LUIGI A, MARTIN-PADURA I et al.: Leukocyte recruitment in the cerebrospinal fluid of mice with experimental meningitis is inhibited by an antibody to junctional adhesion molecule (JAM). J. Exp. Med. (1999) 190:1351–1356.
   PubMed Web of Science ®Google Scholar
• LECHNER F, SAHRBACHER U. SUTER T et al.: Antibodies to the junctional adhesion molecule cause disruption of endothelial cells and do not prevent leukocyte influx into the meninges after viral or bacterial infection. J. Infect. Dis. (2000) 182:978–982.
   Google Scholar
• FREYER D, MANZ R, ZIEGENHORN A et al.: Cerebral endothelial cells release TNF-alpha after stimulation with cell walls of Streptococcus pneumoniae and regulate inducible nitric oxide synthase and ICAM-1 expression via autocrine loops.' Irronunol (1999) 163:4308–4314.
   PubMed Web of Science ®Google Scholar
• LEWCZUK P, REIBER H, TUMANI H: Intracellular adhesion molecule-1 in cerebrospinal fluid- The evaluation of blood-derived and brain-derived fractions in neurological diseases. J. Neuroimmuna (1998) 87:156–161.
   PubMed Web of Science ®Google Scholar
• WEBER JR, ANGSTWURM K, BURGERW, EINHAUPL KM, DIRNAGL U: Anti ICAM-1 (CD 54) monoclonal antibody reduces inflammatory changes in experimental bacterial meningitis. Neuroimmunol (1995) 63:63–68.
   PubMed Web of Science ®Google Scholar
• ALAVI A, SHOA L, LATTANAND C et al.: Brain tumor permeability enhanced by RMP-7, a novel bradykinin agonist. Can J. Infect. Dis. (1995) 6(Suppl. C). Abstact 4153.
   Google Scholar
• ELLIOT PJ, HAYWARD NJ, HUFF MR et al.: Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy. Exp. Neurol (1996) 141:214–224.
   PubMed Web of Science ®Google Scholar
• BARTUS R, ELLIOT P, HAYWARD N et al.: RIVIP-7 selectively increase the uptake of carboplatin into rat brain tumors. Can.! Infect. Dis. (1995) 6(Suppl. C). Abstract 4152.
   Google Scholar
• WASHBURN RG, BARTLETT JA, FORTHAL DN, GRANEY WF: Phase I/II study of RMP-7 and amphotericin B for cryptococcal meningitis in AIDS. 35th Interscience conference on Antimicrobial Agents and Chemotherapy San Francisco (1995). Abstract A51.
   Google Scholar
• SNODGRASS PA, EMERICH DF, LAFRENIERE DL, BARTUS RT: Obligatory tachyphylaxis of bradykinin B2 receptors following increased permeability of blood brain barrier by intravenous cereport. Soc Neurosci Abstracts. (New Orleans) (2000) 26. Abstract 127.4.
   Google Scholar
• WON SOON PARK, YUN SIL CHANG, LEE M: Effect of hypothermia on brain cell membrane function and energy metabolism in experimental Escherichia coil meningitis in the newborn piglet. Neurochem. Res. (2001) 26:369–374.
   PubMed Web of Science ®Google Scholar
• IRAZUZTA JE, OLSON J, KIEFABER MP, WONG H: Hypothermia decreases excitatory neurotransmitter release in bacterial meningitis in rabbits. Brain Res. (1999) 847:143–148.
   PubMed Web of Science ®Google Scholar
• IRAZUZTA JE, PRETZLAFF R, ROWIN M et al.: Hypothermia as an adjunctive treatment for severe bacterial meningitis. Brain Res. (2000) 881:88–97.
   PubMed Web of Science ®Google Scholar
• PELTOLA H: Prophylaxis of bacterial meningitis. Infect. Dis. Clin. North Am. (1999) 13:685–710.
   PubMed Web of Science ®Google Scholar
• RAMSEY ME, ANDREWS N, KACZMARSKI EB, MILLER E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet. (2001) :195–196.
   PubMed Web of Science ®Google Scholar
• •First report of efficacy after introduction.
   Google Scholar
• MOHAMMED I, NASIDI A, ALKALI AS et al.: A severe epidemic of meningococcal meningitis in Nigeria, 1996. Trans. R. Soc. Trop. Med. Hyg. (2000) 94:265–270.
   PubMed Web of Science ®Google Scholar
• POPOVIC T, SACCHI CT, REEVES MW et al.: Neisseria meningitidis serogroup W135 isolates associated with the ET-37 complex. Emerg. Infect. Dis. (2000) 6:428–429.
   PubMed Web of Science ®Google Scholar
• ANONYMOUS. Serogroup Y meningococcal disease - Illinois, Connecticut, and selected areas, United States, 1989-1996. MMWR. (1996) 45:1010–1013.
   PubMedGoogle Scholar
• BJUNE G, HOIBY EA, GRONNESBYJK et al.: Effect of an outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. (1991) 338:1093–1096.
   PubMed Web of Science ®Google Scholar
• SIERRA GVG, CAMPA HC, VARCACEL NM et al.: Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. (1991) 14:195–207.
   PubMedGoogle Scholar
• CARTWRIGHT K, MORRIS R, RUMKE H et al: Immunogenicity and reactogenicity of a novel meningococcal vesicle vaccine containing multiple class 1 (Por A) outer membrane proteins. Vaccine (1999) 17:2612–2619.
   PubMed Web of Science ®Google Scholar
• COQUILLAT D, BRUGE J, DANVE B et al.: Activity and cross-reactivity of antibodies induced in mice by immunization with a group B meningococcal conjugate. Infect. Inman. (2001) 69:7130–7139.
   PubMed Web of Science ®Google Scholar
• FUSCO PC, MICHON F, TAI JY, BLAKE MS. Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. I Infect. Dis. (1997) 175:364–372
   PubMed Web of Science ®Google Scholar
• BLACK S, SHINEFELD H, FIREMAN B et al.: Safety, immunogenicity and efficacy of a heptavalent pneumococcal conjugate vaccine in infancy. Pediatr. Infect. Dis. (2000) 19:187–195.
   Google Scholar
• GEORGE R, MELLEGARO A: Invasive pneumococcal infection: England and Wales 1999. CDR Weekly Report (2001) 11(21).
   Google Scholar